The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06871254




Registration number
NCT06871254
Ethics application status
Date submitted
27/02/2025
Date registered
11/03/2025
Date last updated
8/08/2025

Titles & IDs
Public title
Spinal Cord Injury Neurorecovery Collaboration
Scientific title
Spinal Cord Injury Neurorecovery Collaboration (SCINC) Master Protocol
Secondary ID [1] 0 0
SCINC_MASTER
Universal Trial Number (UTN)
Trial acronym
SCINC
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Spinal Cord Injuries 0 0
Condition category
Condition code
Injuries and Accidents 0 0 0 0
Fractures
Injuries and Accidents 0 0 0 0
Other injuries and accidents
Neurological 0 0 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Therapeutic Intermittent Hypoxia (TIH) + Exercise Training (ET)

Experimental: RRULI: Appendix 1 - In this first arm of SCINC, adults with chronic tetraplegia will be assigned to the RRULI: Appendix 1 intervention.


Other interventions: Therapeutic Intermittent Hypoxia (TIH) + Exercise Training (ET)
TIH in combination with upper limb and respiratory ET. The intervention is predominantly home-based and will be delivered three times per week for six weeks.

Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
At an individual participant level, the Phase IIA study has a single, binary, composite primary outcome to determine if there is a 'signal of benefit', measuring effectiveness, no deterioration, safety and acceptability.
Timepoint [1] 0 0
Baseline and 6-weeks.
Primary outcome [2] 0 0
A) Effectiveness: Increase above baseline that is equal or more than the predefined outcome-specific stated thresholds, on at least ONE of the: Action Reach Arm Test (ARAT), Handheld dynamometer (GRIP) Maximal inspiratory pressure (MIP)
Timepoint [2] 0 0
Baseline and 6 week follow-up
Primary outcome [3] 0 0
B) No deterioration
Timepoint [3] 0 0
Baseline and 6 week follow-up
Primary outcome [4] 0 0
C) Safety - Incidence of Autonomic Dysreflexia (AD) episodes occurring during the intervention period for each individual participant.
Timepoint [4] 0 0
Up to 6 weeks.
Primary outcome [5] 0 0
D) Acceptability - Rate of participant adherence to the intervention, as assessed by monitoring attendance to treatment sessions..
Timepoint [5] 0 0
Up to 6 weeks.
Secondary outcome [1] 0 0
9-hole Peg test
Timepoint [1] 0 0
Baseline and 6-weeks.
Secondary outcome [2] 0 0
Pinch grip dynamometer
Timepoint [2] 0 0
Baseline and 6-weeks.
Secondary outcome [3] 0 0
Penn Spasm Frequency Scale
Timepoint [3] 0 0
Baseline and 6-weeks.
Secondary outcome [4] 0 0
Capabilities of upper extremity questionnaire
Timepoint [4] 0 0
Baseline and 6 weeks
Secondary outcome [5] 0 0
Sleep quality and Obstructive Sleep Apnoea (OSA) will be assessed using polysomnography (a sleep study)
Timepoint [5] 0 0
1 day
Secondary outcome [6] 0 0
Perceived work of breathing
Timepoint [6] 0 0
Baseline and 6-weeks.
Secondary outcome [7] 0 0
Respiratory function will assessed using spirometry.
Timepoint [7] 0 0
Baseline and 6-weeks.
Secondary outcome [8] 0 0
Maximal expiratory pressure (MEP) and sniff nasal inspiratory pressure (SNIP)
Timepoint [8] 0 0
Baseline and 6-weeks
Secondary outcome [9] 0 0
Peak cough flow (L/min)
Timepoint [9] 0 0
Baseline and 6-weeks
Secondary outcome [10] 0 0
Minute Ventilation (Litres)
Timepoint [10] 0 0
Baseline and 6-weeks.
Secondary outcome [11] 0 0
End of tidal breathing oxygen and carbon dioxide saturation.
Timepoint [11] 0 0
Baseline and 6-weeks.
Secondary outcome [12] 0 0
Respiratory Rate measured in breaths per minute.
Timepoint [12] 0 0
Baseline and 6-weeks.
Secondary outcome [13] 0 0
Tidal volume, measured in litres.
Timepoint [13] 0 0
Baseline and 6-weeks.
Secondary outcome [14] 0 0
Ventilation response - assessing mouth pressure (measured in cmH20)
Timepoint [14] 0 0
Baseline and 6-weeks.
Secondary outcome [15] 0 0
Inspiratory time, measured in seconds (s).
Timepoint [15] 0 0
Baseline and 6-weeks.
Secondary outcome [16] 0 0
Inspiratory and expiratory flow, measured in Litres per second (L/s).
Timepoint [16] 0 0
Baseline and 6-weeks.

Eligibility
Key inclusion criteria
SCINC

- Person with SCI

SCINC
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Proven contraindication to intervention

RRULI: Appendix 1 (TIH + ET) study-specific inclusion criteria:

* Adults > 18 years of age
* Able to independently ventilate
* Chronic SCI (>1 years post-injury or impairment onset)
* Tetraplegia (C2-T1 level of injury)
* Evidence of motor incomplete paralysis in the upper limb below the neurological level of injury
* Have a documented management plan for their AD if it occurs.

RRULI: Appendix 1 (TIH + ET) study-specific exclusion criteria:

* Pregnancy
* Medical instability, including current or recent (within the previous 6 weeks) infection or inflammation
* Current or recent (within the previous 6 weeks) pressure ulcers or cutaneous lesions
* Poorly controlled diabetes
* An episode of AD in the previous 6 months that required medical intervention to resolve
* Significant other neurological, psychiatric, pulmonary, cardiovascular, orthopaedic, or oncological conditions.
* Currently taking part in another clinical trial
* Upper limb contracture

Study design
Purpose of the study
Treatment
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Austin Health - Heidelberg
Recruitment postcode(s) [1] 0 0
3084 - Heidelberg

Funding & Sponsors
Primary sponsor type
Other
Name
University of Melbourne
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Institute of Breathing and Sleep
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Government body
Name [2] 0 0
Austin Health
Address [2] 0 0
Country [2] 0 0
Other collaborator category [3] 0 0
Other
Name [3] 0 0
Neuroscience Research Australia
Address [3] 0 0
Country [3] 0 0
Other collaborator category [4] 0 0
Other
Name [4] 0 0
The University of New South Wales
Address [4] 0 0
Country [4] 0 0
Other collaborator category [5] 0 0
Other
Name [5] 0 0
University of Sydney
Address [5] 0 0
Country [5] 0 0
Other collaborator category [6] 0 0
Other
Name [6] 0 0
University of Florida
Address [6] 0 0
Country [6] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
David Berlowitz, PhD
Address 0 0
University of Melbourne
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Laura Stendell
Address 0 0
Country 0 0
Phone 0 0
(+61) 468 862 693
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
De-identified participant level data will be made available for research purposes upon approval of written requests at completion of the trial.

Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Informed consent form (ICF)
When will data be available (start and end dates)?
Unending - beginning nine months following publication with no end date.
Available to whom?
Proposals to access IPD must be directed to the study-specific principal investigator.
Available for what types of analyses?
How or where can data be obtained?


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

No documents have been uploaded by study researchers.